Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Tissue Regenix Group Plc Stock Quote

Tissue Regenix Group Plc (LSE: TRX)

GBX 61.00
(-0.1%)
-GBX 0.05
Price as of April 19, 2024, 11:21 a.m. ET

Tissue Regenix Group Plc Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
TRX +1.65% -89.96% -36.81% -93%
S&P +20.62% +72.50% +11.51% +381%

Tissue Regenix Group Plc Company Info

Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. It operates through the BioSurgery, Orthopaedics & Dental, Cardiac and Other divisions. Its patented decellularisation technology removes DNA and other cellular material from animal and human tissue leaving a cellular tissue scaffold, which is not rejected by the patient's body and can then be used to repair diseased and worn out body parts. The company was founded by Eileen Ingham and John Fisher in May 2006 and is headquartered in Leeds, the United Kingdom.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.